Detalles de la búsqueda
1.
BRAFV600E promotes anchorage-independent growth but inhibits anchorage-dependent growth in hTERT/Cdk4-Immortalized normal human bronchial epithelial cells.
Exp Cell Res
; 439(1): 114057, 2024 Apr 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-38679315
2.
Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan.
Cancer Sci
; 115(2): 507-528, 2024 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-38047872
3.
Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
Cancer Sci
; 115(4): 1296-1305, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38402853
4.
Efficacy and safety of tepotinib in Asian patients with advanced NSCLC with MET exon 14 skipping enrolled in VISION.
Br J Cancer
; 130(10): 1679-1686, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38575731
5.
Phase 2 trial of crizotinib in Japanese patients with advanced NSCLC harboring a MET gene alteration: a Co-MET study.
Int J Clin Oncol
; 2024 May 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-38758397
6.
Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
N Engl J Med
; 383(14): 1328-1339, 2020 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32997907
7.
Effectiveness of crizotinib in patients with ROS1-positive non-small-cell lung cancer: real-world evidence in Japan.
Future Oncol
; 19(37): 2453-2463, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37605861
8.
Resistance to mutant KRASV12-induced senescence in an hTERT/Cdk4-immortalized normal human bronchial epithelial cell line.
Exp Cell Res
; 414(1): 113053, 2022 05 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35149086
9.
Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis.
BMC Cancer
; 22(1): 654, 2022 Jun 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-35698083
10.
Oxytocin receptor is a promising therapeutic target of malignant mesothelioma.
Cancer Sci
; 112(9): 3520-3532, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34115916
11.
The current issues and future perspective of artificial intelligence for developing new treatment strategy in non-small cell lung cancer: harmonization of molecular cancer biology and artificial intelligence.
Cancer Cell Int
; 21(1): 454, 2021 Aug 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34446006
12.
Tepotinib in patients with NSCLC harbouring MET exon 14 skipping: Japanese subset analysis from the Phase II VISION study.
Jpn J Clin Oncol
; 51(8): 1261-1268, 2021 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-34037224
13.
Efficacies of programmed cell death 1 ligand 1 blockade in non-small cell lung cancer patients with acquired resistance to prior programmed cell death 1 inhibitor and development of diabetic ketoacidosis caused by two different etiologies: a retrospective case series.
Endocr J
; 68(5): 613-620, 2021 May 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33790087
14.
Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations.
Int J Mol Sci
; 23(1)2021 Dec 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-35008669
15.
Lorlatinib in previously treated anaplastic lymphoma kinase-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
Cancer Sci
; 111(10): 3726-3738, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32681682
16.
Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies: a prospective study.
Br J Cancer
; 122(6): 771-777, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-32009131
17.
Primary Prophylaxis Indication for Docetaxel Induced Febrile Neutropenia in Elderly Patients with Non-Small Cell Lung Cancer.
Cancer Invest
; 38(7): 424-430, 2020 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-32643445
18.
UHRF1, a Regulator of Methylation, as a Diagnostic and Prognostic Marker for Lung Cancer.
Cancer Invest
; 38(4): 240-249, 2020 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-32212938
19.
Multicenter, placebo-controlled, double-blind, randomized study of fosnetupitant in combination with palonosetron for the prevention of chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy.
Cancer
; 125(22): 4076-4083, 2019 Nov 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31381152
20.
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV.
Int J Clin Oncol
; 24(7): 731-770, 2019 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-31049758